These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Prevention of cardiovascular events by the antihypertensive treatment using amlodipine and perindopril in comparison with the use of atenolol and bendroflumethiazide. The ASCOT (Anglo-Scandinavian Outcomes Trail: blood pressure lowering arm) study results--multicentre, randomised, controlled trial. Landmark in the development of opinions on combination therapy in hypertension? (comment)].
    Author: Widimský J.
    Journal: Vnitr Lek; 2005 Dec; 51(12):1394-6, 1398-9. PubMed ID: 16430107.
    Abstract:
    It is a multicentre, prospective, randomised controlled trial in 19 257 patients with hypertension aged 40-79 years with at least three cardiovascular risk factors. After 5,5 years median follow-up fewer individuals on amlodipine + perindopril had a primary endpoint (429 vs 474, HR 0.90, p = 0.1052), fatal and non-fatal stoke (327 vs 422, HR 0.77, p = 0.0003), total cardiovascular events and procedures 1362 vs 1602, 0.84, p = 0.0001) and all cause mortality (738 vs. 820, HR 0.89, p = 0.025). The incidence of developing diabetes was also less on the amlodipine + perindopril based regimen (567 vs 799, HR 0,70, p = 0.0001). The amlodipine-perindopril based regiment prevented more major cardiovascular events and induced less diabetes than the atenolol-based regimen. These results may have in implications with respect to optimum combinations of antihypertensive drugs.
    [Abstract] [Full Text] [Related] [New Search]